11512
J. Am. Chem. Soc. 1998, 120, 11512-11513
Relative Configuration and Conformation of Key In-
termediates for Matrix Metalloproteinase Inhibitors
as Determined by NMR-Based Restrained Simulated
Annealing and Validated by X-ray Analysis
Hans Matter,* Martin Knauf, Wilfried Schwab, and
Erich F. Paulus
Hoechst Marion Roussel
Core Research Functions & Chemical Research
D-65926 Frankfurt am Main, Germany
ReceiVed July 9, 1998
ReVised Manuscript ReceiVed September 8, 1998
The information about relative and absolute configuration of
stereogenic centers in natural products and synthetic key inter-
mediates is indispensable for modern medicinal chemistry. To
achieve spatial complementarity between ligands and specific
target enzymes, an understanding of stereoselective transforma-
tions is required. Here we describe the application of a strategy
to simultaneously determine configuration and conformation of
key intermediates in the synthesis of enzyme inhibitors using 2D
NMR spectroscopy and simulated annealing1 including a floating
chirality approach.2
Since matrix metalloproteinases are of growing interest in
pharmaceutical research,3 we have investigated key intermediates
for stromelysin (MMP-3) inhibitors with S1′ directed biphenyl-
sulfonyl side chains.4 Their relative configurations were unam-
biguously obtained using this approach and could be validated
using X-ray structure analysis. To our knowledge, this is the
first example of this strategy combined with an independent
validation showing its potential to rapidly obtain relevant stere-
ochemical information.5
The synthetic route (cf. Figure 1) started from (R)-tetrahy-
droisoquinolin-3-carboxylate 1, which was N-sulfonated.6 2 was
converted to the aldehyde 4 by reduction to 3 using BMS7 and
oxidation using o-iodoxybenzoic acid IBX.8 The loss of optical
rotation from 3 to 4 indicates racemization despite the extremely
mild conditions. Due to lack of stability, 4 was directly converted
to the configurationally stable N-methylnitrone 5. Heating a
solution of 5 resulted in 1,3-dipolar cycloaddition to give the
desired isoxazolidines 6 in a 48.6:51.4 ratio of 6a (RSS/SRR, trans)
and 6b (RSR/SRS, cis). The low cis/trans stereoselectivity has
been overcome in special cases.9 The stereodirecting effect of
R-chiral nitrones during olefin cycloaddition was described using
different transition state models.10 Our data suggest that cycload-
dition of tetrahydroisoquinolin nitrones preferably results in 4R/
3S (4S/3R) stereochemistry.
Figure 1. Synthesis of both diastereomeric MMP-3 inhibitor key
intermediates 6a and 6b.
1
After the assignment of H NMR resonances11 for 6a and 6b
(cf. Supporting Information), distance constraints were extracted
from 2D NOESY and ROESY spectra by conversion of cross-
peak volumes into interproton distances using the isolated spin
pair approximation (ISPA). Thirty-one and 26 nontrivial distance
constraints were obtained for 6a and 6b, respectively.12 In
addition, homonuclear J-coupling constants (cf. Supporting
Information) were converted into dihedral angle information.13
For both compounds the NMR spectra indicate the existence of
a single preferred conformation.14
The NOE restrained simulated annealing calculations1 were
performed using SYBYL.15,16 Since it is not possible to determine
absolute configurations in distance space, carbon C4 was set to
R-chirality. Thus, four different starting configurations for
carbons C4, C3, and C1 (RSS, RSR, RRS, and RRR) were
considered for each intermediate. The NMR-derived distance
constraints were applied as a biharmonical function. An energetic
force field was used where experimentally derived distance
constraints have higher force constants than the terms maintaining
individual atom chiralities. Thus, chiral centers are allowed to
invert during the simulation. For each starting configurations,
50 structures were calculated, which were all combined for
analysis yielding 200 individual structures for 6a and 6b,17
respectively.
Acceptable structures were selected on the basis of the
maximum pairwise rmsd violations18 as objective criteria. For
each structure, the maximum rmsd to all structures with lower
(10) (a) Vasella, A.; Voeffray, R. HelV. Chim. Acta 1982, 65, 1134-1144.
(b) DeShong, P.; Li, W.; Kennington, J. W.; Ammon, H. L. J. Org. Chem.
1991, 56, 1364-1373. (c) Baggiolino, E. G.; Iacobelli, J. A.; Hennessy, B.
M.; Batcho, A. D.; Sereno, J. F.; Uskokovic, M. R. J. Org. Chem. 1986, 51,
3098-3108.
(11) NMR samples were prepared by dissolving 6a and 6b in 0.6 mL of
CDCl3. NMR spectra were obtained in the phase sensitive mode on a BRUKER
DRX 600 spectrometer at 300 K using TPPI for quadrature detection in F1.
For ROESY experiments, a mixing time of 150 ms was used for both epimers.
The mixing times for the NOESY experiments of 6a and 6b were set to 600
ms and 1 s, respectively.
(12) For nondiastereotopically assigned CH2 protons and methyl groups,
90 and 100 pm were added to the upper bounds as pseudoatom corrections
(Wu¨thrich, K. NMR of Proteins and Nucleic Acids; Wiley: New York, 1986).
Upper and lower limits have been set to (10% of the calculated distances.
(13) A Karplus-type of equation (Karplus, M. J. Chem. Phys. 1959, 30,
11-15) with the following parameters was used: A ) 9.5, B ) -1.6, C )
1.8 (DeMarco, A.; Llinas, M.; Wu¨thrich, K. Biopolymers 1978, 17, 617-
636).
(14) The diastereotopic protons show significant chemical shift differences
and different vicinal coupling constants. The line shapes of the resonance
signals do not indicate any conformational heterogeneity (Kessler, H. Angew.
Chem., Int. Ed. Engl. 1982, 21, 512-523).
(15) SYBYL Molecular Modelling Package, Versions 6.3, Tripos, St. Louis,
MO, 1996.
(16) All energy calculations were based on the TRIPOS 6.0 force field
(Clark, M.; Cramer, R. D., III; Van Opdenbosch, N. J. Comput. Chem. 1989,
10, 982-1912) including Gasteiger-Marsili charges (Gasteiger, J.; Marsili,
M. Tetrahedron 1980, 36, 3219-3228).
* To whom the correspondence should be addressed. Phone: ++49-69-
(1) Nilges, M.; Clore, G. M.; Gronenborn, A. M. FEBS Lett. 1988, 229,
317-324.
(2) Weber, P. L.; Morrison, R.; Hare, D. J. Mol. Biol. 1988, 3, 483-487.
(3) (a) Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Curr. Pharm.
Des. 1996, 2, 624-661. (b) Hagmann, W. K.; Lark, M. W.; Becker, J. W.
Ann. Rep. Med. Chem. 1996, 231-240. (c) Ye, Q. Z.; Hupe, D.; Johnson, L.
Curr. Med. Chem. 1996, 3, 407-418.
(4) Esser, C. K.; Bugianesi, R. L.; Caldwell, C. G.; Chapman, K. T.; Durette,
P. L.; Girotra, N. N.; Kopka, I. E.; Lanza, T. J.; Levorse, D. A.; MacCoss,
M.; Owens, K. A.; Ponpipom, M. M.; Simeone, J. P.; Harrison, R. K.;
Niedzwiecki, L.; Becker, J. W.; Marcy, A. I.; Axel, M. G.; Christen, A. J.;
McDonnell, J.; Moore, V. L.; Olszewski, J. M.; Saphos, C.; Visco, D. M.;
Shen, F.; Colletti, A.; Krieter, P. A.; Hagmann, W. K. J. Med. Chem. 1997,
40, 1026-1040.
(5) For a pioneering approach, see: Reggelin, M.; Hoffmann, H.; Ko¨ck,
M.; Mierke, D. F. J. Am. Chem. Soc. 1992, 114, 3272-3277.
(6) Experimental conditions, see Supporting Information.
(7) Lane, C. F. Aldrichim. Acta 1977, 10, 41-51.
(8) (a) Frigerio, M.; Santagostino, M.; Sputore, S.; Palmisano, G. J. Org.
Chem. 1995, 60, 7271-7276. (b) Plumb, J. B.; Harper, D. J. Chem. Eng.
News 1990, 3.
(9) Mukai, C.; Kim, I. J.; Cho, W. J.; Kido, M.; Hanaoka, M. J. Chem.
Soc., Perkin Trans. 1 1993, 2494-2503.
10.1021/ja982415e CCC: $15.00 © 1998 American Chemical Society
Published on Web 10/27/1998